http://www.cancercompass.comCancerCompass is an online community committed to offering people living with cancer a place to receive cancer information and news, share knowledge, and share cancer treatment experiences. To learn more, visit our site today.en-us@copy; Copyright 2008, International Capital & Management Company, LLLP. All Rights Reserved.Thu, 24 Jul 2008 07:44:31 CDTThu, 24 Jul 2008 07:44:31 CDTCancercompass.com: prostate cancer60http://www.cancercompass.com/graphics/mini-logo.gifhttp://www.cancercompass.comhttp://www.cancercompass.com/cancer-news/1,14485,00.htm?rss=yhttp://www.cancercompass.com/cancer-news/1,14485,00.htm?rss=y The House of Representatives today approved historic legislation calling for increased support from the public and private sectors for the development of innovative advanced imaging technologies for early diagnosis and treatment of prostate cancer - the most common major cancer in the United States and the second-most-lethal cancer in men. House Resolution 353, introduced by Reps. Elijah Cummings (D-Md.) and Dan Burton (R-Ind.), has broad bipartisan support, with more than 100 cosponsors. Reflecting the disproportionate impact of prostate cancer on the African-American community, including a 60 percent higher incidence rate and more than 2.5 times higher mortality rate, more than 30 members of the Congressional Black Caucus cosponsored th...Fri, 18 Jul 2008 00:00:00 CDThttp://www.cancercompass.com/cancer-news/1,14486,00.htm?rss=yhttp://www.cancercompass.com/cancer-news/1,14486,00.htm?rss=y SEATTLE -- Dendreon Corporation today announced that the Company has initiated a Phase 2 trial of PROVENGE(R) (sipuleucel-T), Dendreon's investigational active cellular immunotherapy for the treatment of prostate cancer, in men with localized prostate cancer who are scheduled to undergo a radical prostatectomy. The single-center trial called NeoACT (NEOadjuvant Active Cellular immunoTherapy), or P07-1, which is being conducted at UCSF Helen Diller Family Comprehensive Cancer Center, has begun enrolling approximately 40 patients. NeoACT is the first of two new Phase 2 trials of PROVENGE being initiated this year. Each patient will receive a complete course of active treatment over a one-month period beginning six to se...Fri, 18 Jul 2008 00:00:00 CDThttp://www.cancercompass.com/cancer-news/1,14482,00.htm?rss=yhttp://www.cancercompass.com/cancer-news/1,14482,00.htm?rss=y FARMINGDALE, N.Y. -- Misonix, Inc., a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of cancer and worldwide for other acute health conditions, has received 510(k) clearance from the U.S. Food and Drug Administration ("FDA") to market its Sonatherm 600i High Intensity Focused Ultrasound ("HIFU") Soft Tissue Ablation System in the United States, which will be used to ablate certain soft tissue lesions, excluding the prostate gland, in general surgery. The Sonatherm 600i System is an evolution of the Company's Sonatherm 600 System that received FDA clearance in January, 2006. The Sonatherm 600i System adds imagery and motion capability. To date, the two Sonathe...Fri, 18 Jul 2008 00:00:00 CDThttp://www.cancercompass.com/cancer-news/1,14483,00.htm?rss=yhttp://www.cancercompass.com/cancer-news/1,14483,00.htm?rss=y There's truth in the old saw "an apple a day keeps the doctor away." Apples contain phytonutrients that lower cholesterol and reduce the risk of stroke, prostate cancer, type II diabetes and asthma. But just in time for the peak summer watermelon consumption season and National Watermelon Day on Aug. 3, researchers at Texas A&M University announced that watermelons have surprising health properties too. The big fruit contains citrulline, which, if consumed in large quantities, could have a Viagra-like effect. A July 3 Associated Press article reported citrulline converts to an amino acid that boosts nitric oxide and relaxes blood vessels. It has the "same basic effect that Viagra has to treat erectile dysfunction," sa...Fri, 18 Jul 2008 00:00:00 CDThttp://www.cancercompass.com/cancer-news/1,14484,00.htm?rss=yhttp://www.cancercompass.com/cancer-news/1,14484,00.htm?rss=y Health Discovery Corporation ("HDC") announced the successful phase II clinical trial results for HDC's new gene-based molecular diagnostic test for prostate cancer licensed exclusively to Clarient, in which HDC will receive a 30 percent royalty on each test performed based on the per test reimbursement received by Clarient. In addition to the commercialization license HDC granted to Clarient, HDC retained the right to also commercialize this molecular diagnostic test for prostate cancer in one or more clinical laboratories that HDC elects to own and/or operate. Results from both the Phase I and Phase II clinical validation studies now completed at Clarient with prostate tissues obtained from multiple sites, including those tested in col...Fri, 18 Jul 2008 00:00:00 CDThttp://www.cancercompass.com/cancer-news/1,14469,00.htm?rss=yhttp://www.cancercompass.com/cancer-news/1,14469,00.htm?rss=y THOUSAND OAKS, Calif. -- Amgentoday announced findings from a three-year pivotal Phase 3 placebo-controlled trial evaluating denosumab in the treatment of bone loss in men undergoing androgen deprivation therapy (ADT) for non-metastatic prostate cancer. In this study of more than 1,400 men, denosumab treatment produced statistically significantly greater increases in bone mineral density (BMD) at the lumbar spine (primary endpoint) and non-vertebral sites compared with placebo at multiple time points. These improvements in BMD were consistent with those seen in other denosumab studies evaluating BMD in women with breast cancer receiving aromatase inhibitor therapy, and in post-menopausal women with low bone mass. Durin...Tue, 15 Jul 2008 00:00:00 CDThttp://www.cancercompass.com/cancer-news/1,14438,00.htm?rss=yhttp://www.cancercompass.com/cancer-news/1,14438,00.htm?rss=y BOSTON--Scientists at Dana-Farber Cancer Institute report they have blocked the development of prostate tumors in cancer-prone mice by knocking out a molecular unit they describe as a "powerhouse" that drives runaway cell growth. In an article that is being published as an advanced online publication by the journal Nature, the researchers say the growth-stimulating molecule called p110beta -- part of a cellular signaling network disrupted in several common cancers -- is a promising target for novel cancer therapies designed to shut it down. The report's lead authors are Shidong Jia, MD, PhD, Zhenning Liu, PhD, Sen Zhang PhD, and Pixu Liu, MD, PhD. The p110beta molecule and a counterpart, p110alpha, are "isoforms" -- slightly different...Fri, 04 Jul 2008 00:00:00 CDThttp://www.cancercompass.com/cancer-news/1,14439,00.htm?rss=yhttp://www.cancercompass.com/cancer-news/1,14439,00.htm?rss=y The House of Representatives today approved historic legislation calling for increased support from the public and private sectors for the development of innovative advanced imaging technologies for early diagnosis and treatment of prostate cancer - the most common major cancer in the United States and the second-most-lethal cancer in men. House Resolution 353, introduced by Reps. Elijah Cummings (D-Md.) and Dan Burton (R-Ind.), has broad bipartisan support, with more than 100 cosponsors. Reflecting the disproportionate impact of prostate cancer on the African-American community, including a 60 percent higher incidence rate and more than 2.5 times higher mortality rate, more than 30 members of the Congressional Black Caucus cosponsored t...Fri, 04 Jul 2008 00:00:00 CDThttp://www.cancercompass.com/cancer-news/1,14440,00.htm?rss=yhttp://www.cancercompass.com/cancer-news/1,14440,00.htm?rss=y A simple blood test screening for a panel of biomarkers can accurately predict whether a patient who has had prostate cancer surgery will have a recurrence or spread of the disease. Calling their findings a major step forward in prostate cancer care, Texas researchers report in the June 15 issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, that the presence of seven of these biomarkers can predict prostate cancer risk with 86.6 percent reliability. This is at least 15 percentage points higher than standard clinical measures currently in use, the researchers say. "We have been looking at these biomarkers for the past 10 to 15 years in the laboratory, but now we can translate these findings int...Fri, 04 Jul 2008 00:00:00 CDThttp://www.cancercompass.com/cancer-news/1,14423,00.htm?rss=yhttp://www.cancercompass.com/cancer-news/1,14423,00.htm?rss=y NEW YORK -- Prostate cancer is the second leading cause of death among American males, but when caught early, prostate cancer has a 90% cure rate. According to Dr. David Samadi, Chief, Division of Robotics and Minimally Invasive Surgery, Department of Urology, at Mount Sinai Medical Center, "The key to fighting prostate cancer is not to wait until there are warning signs, because by then it may be too late." The tendency of prostate cancer to grow without causing noticeable symptoms leads doctors to recommend that men over 50 get screened every year. However, Dr. Samadi recommends that anyone with a strong family history of the disease or other risk factors get screened at age 40. Routine screening for prostate canc...Tue, 01 Jul 2008 00:00:00 CDThttp://www.cancercompass.com/cancer-news/1,14421,00.htm?rss=yhttp://www.cancercompass.com/cancer-news/1,14421,00.htm?rss=y NEW YORK -- Prostate cancer is the second leading cause of death among American males, but when caught early, prostate cancer has a 90% cure rate. According to Dr. David Samadi, Chief, Division of Robotics and Minimally Invasive Surgery, Department of Urology, at Mount Sinai Medical Center, "The key to fighting prostate cancer is not to wait until there are warning signs, because by then it may be too late." The tendency of prostate cancer to grow without causing noticeable symptoms leads doctors to recommend that men over 50 get screened every year. However, Dr. Samadi recommends that anyone with a strong family history of the disease or other risk factors get screened at age 40. Routine screening for prostate canc...Tue, 01 Jul 2008 00:00:00 CDThttp://www.cancercompass.com/cancer-news/1,14415,00.htm?rss=yhttp://www.cancercompass.com/cancer-news/1,14415,00.htm?rss=y CHARLOTTE, N.C. -- USHIFU, LLC, the exclusive distributor of the minimally invasive Sonablate(R) 500 for prostate cancer treatment in North and South America, announced that the June 16, 2008 edition of ABC News NIGHTLINE featured a segment on high intensity focused ultrasound (HIFU) for treating prostate cancer outside of the United States using the Sonablate(R) 500. According to the segment, men diagnosed with prostate cancer have the ability to travel outside of the United States to receive HIFU, a non invasive, outpatient procedure for prostate cancer. The segment failed to mention that the Sonablate(R) 500 HIFU treatment is currently involved in two different FDA-approved clinical trials in the United States to...Fri, 27 Jun 2008 00:00:00 CDThttp://www.cancercompass.com/cancer-news/1,14416,00.htm?rss=yhttp://www.cancercompass.com/cancer-news/1,14416,00.htm?rss=y WASHINGTON -- The House of Representatives today approved historic legislation calling for increased support from the public and private sectors for the development of innovative advanced imaging technologies for early diagnosis and treatment of prostate cancer - the most common major cancer in the United States and the second-most-lethal cancer in men. House Resolution 353, introduced by Reps. Elijah Cummings (D-Md.) and Dan Burton (R-Ind.), has broad bipartisan support, with more than 100 cosponsors. Reflecting the disproportionate impact of prostate cancer on the African-American community, including a 60 percent higher incidence rate and more than 2.5 times higher mortality rate, more than 30 members of the Congress...Fri, 27 Jun 2008 00:00:00 CDThttp://www.cancercompass.com/cancer-news/1,14418,00.htm?rss=yhttp://www.cancercompass.com/cancer-news/1,14418,00.htm?rss=y WALTHAM, Mass. -- Millennium Research Group (MRG) conducted a detailed survey of over 140 US and European based urologists during the recent 2008 American Urological Association (AUA) Annual Meeting. Results of this study are analyzed in the US and European Urologist Survey: Prostate Cancer Treatment Trends 2008 report. Data from the study suggests that several minimally invasive prostate cancer treatment options are underused in both the US and Europe. US urologists indicated that cryosurgery was underused, while European urologists felt that both cryosurgery and high-intensity focused ultrasound (HIFU) were underused. In both regions, insufficient data supporting the treatments and the need to refer patients to anothe...Fri, 27 Jun 2008 00:00:00 CDThttp://www.cancercompass.com/cancer-news/1,14394,00.htm?rss=yhttp://www.cancercompass.com/cancer-news/1,14394,00.htm?rss=y SARASOTA, Fla. -- The following statement was issued today by Diagnostic Center for Disease: "There is currently no convincing evidence that early screening, detection, and treatment improve mortality. Limitations in prostate cancer screening include potential adverse health effects associated with false-positive and negative results, and treatment side effects." Policy Statement from the American College of Preventive Medicine, published in the American Journal of Preventive Medicine, February 2008 There were an estimated 50,000 robotic prostatectomies performed in 2007(1). It is projected that the number could double in 2008. Robot assisted laparoscopic prostatectomy (RALP) is now generall...Tue, 24 Jun 2008 00:00:00 CDT